Skip to main content
. 2023 Jan 26;14:1120308. doi: 10.3389/fphys.2023.1120308

FIGURE 6.

FIGURE 6

Treatment of the CKD-MBD inhibits VSMC transdifferentiation to osteocytic type cells, inhibiting vascular calcification, decreasing sclerostin secretion, and stimulating bone formation. This would produce expected efficacy in cardiovascular and skeletal outcomes. The changes in sclerostin levels during treatment make it a biomarker of progress.